

Myelosuppression Risk From Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors, Carboplatin Chemotherapy, or Both in *EGFR*-Mutated Non-small Cell Lung Cancer (NSCLC)

Nicolas Girard,¹ Stephen V. Liu,² William William,³ Kassandra Schaible,⁴ Daniela Junqueira,⁵ Heather Burnett,⁵ Parthiv Mahadevia,⁶ Marc Chioda,⁶ Joshua M. Bauml,⁷ Natasha Leighl⁸

¹Institut du Thorax Curie-Montsouris, Paris, France, and Paris Saclay University, UVSQ, Versailles, France; ²Georgetown Lombardi Comprehensive Cancer Center, Washington DC, USA; ³Centro Oncológico BP, Beneficência Portuguesa de São Paulo, and Grupo Oncoclínicas, São Paulo, Brazil; ⁴Evidera, Bethesda, MD, USA; ⁵Evidera, Montreal, QC, Canada; ⁶Janssen Research & Development, Raritan, NJ, USA; ⁷Janssen Research & Development, Spring House, PA, USA; ⁸Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

<https://www.congresshub.com/Oncology/ELCC2024/Amivantamab/Girard>

The QR code is intended to provide scientific information for individual reference, and the information should not be altered or reproduced in any way.



Disclosures

NG: Consulting/advisory role for AbbVie, AstraZeneca, BMS, Boehringer Ingelheim, GSK, Janssen, Lilly, MSD, Novartis, Pfizer, PharmaMar, Roche, Sanofi, and Takeda; travel/accommodation expenses from AstraZeneca, BMS, MSD Oncology, and Roche; and research funding from AstraZeneca, Boehringer Ingelheim, and Roche.

SVL: Research funding from AbbVie, Alkermes, Arcus, AstraZeneca, Elevation Oncology, Ellipses, Genentech, Gilead, Merck, Merus, Nuvalent, RAPT, and Turning Point Therapeutics; consulting/advisory role for AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, BMS, Catalyst, Daiichi Sankyo, Eisai, Elevation Oncology, Genentech/Roche, Gilead, Guardant Health, Janssen, Jazz Pharmaceuticals, Merck, Merus, Mirati, Novartis, Pfizer, Regeneron, Sanofi, Takeda, and Turning Point Therapeutics; and data safety monitoring or advisory board for Candel Therapeutics.

WW: Research funding from AstraZeneca, Janssen, Merck, BMS, Sanofi, and MSD; consulting/advisory role for Roche/Genentech, AstraZeneca, Janssen, Merck, BMS, Sanofi, MSD, Pfizer, Takeda, Novartis, Boehringer Ingelheim, Lilly, and Bayer; honoraria from Roche/Genentech, AstraZeneca, Janssen, Merck, BMS, Sanofi, MSD, Pfizer, Takeda, Novartis, Boehringer Ingelheim, Lilly, and Bayer; travel/accommodation expenses from AstraZeneca, Merck, BMS, Daiichi Sankyo, Sanofi, and Janssen; data safety monitoring or advisory board for io9; leadership or fiduciary role for Sociedade Brasileira de Oncologia Clínica and Latin American Cooperative Oncology Group (unpaid); and stock or stock options from io9.

KS, DJ, HB: Employees of Evidera, a Thermo Fisher company, which received funding to complete this work.

PM, MC, JMB: Employees and shareholders of Johnson & Johnson.

NL: Received fees for independent continuing medical education from AstraZeneca, BMS, and MSD; and research funding from Array.



Introduction

- Approximately 30% of global NSCLC cases are found to have an epidermal growth factor receptor (*EGFR*) mutation¹
- Tyrosine kinase inhibitors (TKIs) are the standard of care for *EGFR*-mutated NSCLC; however, resistance to TKIs is common and treatment is often supplemented with chemotherapy^{2,3}
- The addition of carboplatin-doublet chemotherapy (CBCT) to *EGFR*-TKIs has been evaluated in *EGFR*-mutated NSCLC; however, both classes of agents are associated with myelosuppression including neutropenia, anemia, and/or thrombocytopenia³
- A systematic literature review was conducted to summarize rates of myelosuppressive events following treatment with *EGFR*-TKIs alone or in combination with CBCT



Methods


- Systematic searches were conducted on June 19, 2023, in Embase (Elsevier), MEDLINE (National Library of Medicine), CENTRAL and the Cochrane Database of Systematic Reviews via Ovid® (Wolters Kluwer) to identify publications of interest
 - Additional hand searches of conference proceedings from five key meetings were also conducted
- Eligible studies were clinical trials published between 2010 and 2023 that evaluated safety outcomes following administration of the treatments of interest in patients with advanced/metastatic NSCLC with a confirmed EGFR mutation
- Key safety outcomes included any grade and grade 3+ neutropenia, anemia, and thrombocytopenia



Systematic Literature Review Results

- A total of 1764 unique publications were screened, of which 20 were included representing 16 unique clinical trials in the review (14 of which were randomized controlled trials)
- Twelve trials evaluated first-line treatments, and 4 evaluated second-line or later treatments
 - All the included trials assessed first- and third-generation TKIs; none assessed second-generation TKIs
- The number of events and participants evaluated across the included trials were used to calculate the weighted average incidence of anemia, neutropenia, and thrombocytopenia
 - This was calculated as total events across all trials divided by the total number of participants across all trials

PRISMA study attrition



Average Incidence of Any Grade and Grade 3+ Myelosuppression Events

- The average incidence of any-grade myelosuppressive events for first-generation TKIs plus CBCT versus CBCT alone was estimated to be 63.4% versus 44.7% for anemia, 61.8% versus 38.9% for neutropenia, and 48.2% versus 35.1% for thrombocytopenia
- The average incidence for any-grade myelosuppressive events for third-generation TKIs plus CBCT was 71.7% for anemia, 88.7% for neutropenia, and 73.6% for thrombocytopenia
- The average incidence of grade 3+ events followed a similar trend with increased rates of anemia and thrombocytopenia for those treated with third-generation TKIs plus CBCT versus CBCT or third-generation TKIs alone


			Anemia	Neutropenia	Thrombocytopenia
Treatment category	Grade	No. of studies	Mean (%)	Mean (%)	Mean (%)
First-generation TKI	Any	2	15.7	4.7	4.7
	3+	5	1.1	0.3	0.0
Third-generation TKI	Any	1	7.5	7.9	10.0
	3+	3	1.2	2.9	2.6
CBCT	Any	2	44.7	38.9	35.1
	3+	5	15.3	57.2	12.2
First-generation TKI + CBCT	Any	2	63.4	61.8	48.2
	3+	7	16.1	42.0	9.1
Third-generation TKI + CBCT	Any	2	71.7	88.7	73.6
	3+	5	28.5	39.2	29.2

CBCT, carboplatin-doublet chemotherapy; TKI, tyrosine kinase inhibitor.



Range in Incidence of Myelosuppression Events

- The incidence of any-grade and grade 3+ myelosuppression events ranged widely across trials
 - Most studies did not evaluate cytopenic events during the first 14 days of treatment when the rate of cytopenia is highest
- When EGFR-TKIs were added to CBCT, the rates of myelosuppression increased compared with that of TKI alone
- Treatment with first-generation TKIs plus CBCT resulted in similar average rates of grade 3+ myelosuppression when compared to CBCT alone. Average rates of any grade events were higher
- The risk of cytopenic events was highest for third-generation TKIs in combination with CBCT, especially for neutropenia and thrombocytopenia



CBCT, carboplatin-doublet chemotherapy; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor. Yellow bars indicate average incidence across included studies.



Key Takeaway



Treatment with EGFR-TKIs in combination with CBCT results in higher rates of cytopenic events than seen with CBCT or TKI monotherapy. The rate of events was observed to be highest for third-generation TKIs plus CBCT

This material is distributed for scientific purposes on Janssen Science, and is not for promotional use



Conclusions

- ✓ Third-generation EGFR-TKIs in combination with CBCT resulted in higher rates of myelosuppression than those seen with chemotherapy alone
- ✓ The above safety signal was not as pronounced for first-generation EGFR-TKIs in combination with CBCT
- ✓ These trends were consistent for any-grade anemia, neutropenia, and thrombocytopenia, as well as grade 3+ anemia and thrombocytopenia

This material is distributed for scientific purposes only. Janssen Science, and is not for promotional use



Acknowledgments

- This study was funded by Janssen Research & Development, LLC



The QR code is intended to provide scientific information for individual reference, and the information should not be altered or reproduced in any way.

This material is distributed for scientific purposes on Janssen Science, and is not for promotional use